Paper Alert

Dear Readers,

The Paper Alert section of Bladder Cancer reviews new publications (usually published within the prior 6 months) that will be of interest to most clinicians and scientists in the bladder cancer field, but which may have been overlooked by many super specialists (clinicians and researchers). They are selected not only because they are important in their own right but also because they may influence how we care for patients, and because they may give us new perspectives on common problems. The selection is done by myself and approved by the Editors-in-Chief before publication.

Edward Messing MD, FACS
Professor of Urology and Oncology
University of Rochester School of Medicine
Rochester, NY, USA

Paper Alert 2

Bladder cancer (BC) occurs roughly 3 times as often in men as women, not only in the United States, but worldwide [1]. This ratio has changed little over the past 30 years despite women entering the male workplace and increasing their relative exposure to bladder carcinogens such as those in cigarette smoke.

Paper Alert 1

This is the initial edition of Paper Alert in Bladder Cancer. Because of two recent shortages of BCG for treating non-muscle invasive (NMI) bladder cancer, (two to three years ago of the Connaught strain, and within the past year of the Tice strain), and with strains used in other countries not available in the United States, urologists have been faced with several problems in managing patients with NMI BC, particularly those with high grade disease.